- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Cytogen’s Quadramet wins FDA nod
Monoclonal antibody developer Cytogen of Princeton, NJ, has received the Food and Drug Administration's go-ahead to market its Quadramet cancer therapy agent for relieving pain in patients whose cancer has spread to the bone. Quadramet is indicated in
Monoclonal antibody developer Cytogen of Princeton, NJ, has received the Food and Drug Administration's go-ahead to market its Quadramet cancer therapy agent for relieving pain in patients whose cancer has spread to the bone. Quadramet is indicated in patients with osteoblastic metastatic bone lesions, which can be caused by prostate, bone, or breast cancer.
Quadramet will be marketed in the U.S., Canada, and Latin America by Du Pont Merck Radiopharmaceuticals, with shipments scheduled to begin this quarter. The news of the FDA's action caused Cytogen's stock to surge 56, or 11%, to end at $5.81 on March 31, the day the news was announced.
In other Cytogen news, the company said that it has begun phase I clinical trials investigating the use of Quadramet for treating patients with refractory rheumatoid arthritis. The study will be conducted at the University of Iowa and will enroll about 30 patients.
Another Cytogen technology, prostate specific membrane antigen (PSMA), has shown promise in preliminary research as a possible vaccine to fight prostate cancer. Cytogen has licensed PSMA technology to a company called Prostagen, which is researching the use of immunotherapy for advanced prostate cancer.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
